We went on to show that genetic or pharmacological inhibition of TRPML1 reduced the proliferation of many different oncogenic HRAS-expressing cancer cell lines via attenuation of the MEK–ERK pathway (Figure 1). The gene discussed is HRAS; the disease is cancer.